Boris Peaker, Ph.D., is Executive Director and Senior Analyst with Oppenheimer & Co. Inc., covering the biotechnology sector. Prior to joining Oppenheimer & Co. Inc., he was an Analyst at Rodman & Renshaw, covering small and midcap biotech companies across multiple therapeutic areas. Prior to Rodman & Renshaw, Dr. Peaker covered mid- and large-cap U.S.-based biopharmaceutical and biotechnology companies at Cowen Group. He began his career as a Consultant at Keelin Reeds Partners in Palo Alto, California, working exclusively with biotechnology and pharmaceutical companies on asset valuation, R&D portfolio management, M&A strategy, and royalty and equity financing. He holds a Ph.D. in biophysics from Stanford University and a dual B.S. in physics and chemistry from SUNY Stony Brook.
Strong Outlook for Orphan and Oncology Treatments
April 03, 2014
Oncology and Orphan Drugs Retain Pricing Power
August 14, 2013
Emerging-Growth Opportunities in Oncology Biotech
August 29, 2012